Skip to content
Aster DM Healthcare logo

Aster DM Healthcare

Aster DM Quality Care Ltd

ASTERDM NSE
₹719.55 +38.20 (+5.61%)
P/E
117.00
View as Markdown
MCP
Close 4 Nov 2026 ₹719.55 +32.30 +4.70% 1Y
Start ₹687.25

Key Fundamentals

MidcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
11.60%
Debt to Equity
0.62
EPS (TTM)
₹6.15
Book Value
₹48.26
Market Cap
—
P/E (TTM)
117.00
P/B
14.91
ROE
11.30%
Dividend Yield
0.44%
EBITDA
₹1,027 Cr
52W High
₹891.30
52W Low
₹519.10
Day Range
₹679.05 – ₹729.00
Volume
17,82,568

Peer Comparison

Healthcare › Healthcare Services › Hospitals › Hospital

Aster DM Healthcare peer comparison
Apollo Hospitals
₹8,599.5059.18₹1,22,850 Cr13.040.24%21.20%17.40%₹26,430 Cr₹2,171 Cr
Max Healthcare Institute
₹927.1561.89₹89,301 Cr7.960.22%14.70%14.70%₹8,712 Cr₹1,457 Cr
Manipal Health Enterprises
₹667.2088.96₹86,479 Cr5.340.00%6.64%8.30%₹11,400 Cr₹906 Cr
Aster DM Healthcare (this company)
₹719.55117.00₹59,927 Cr14.910.44%11.30%11.60%₹4,876 Cr₹363 Cr
Fortis Healthcare
₹790.6556.96₹59,706 Cr6.030.13%11.20%13.40%₹9,506 Cr₹1,070 Cr
Narayana Hrudayalaya
₹1,931.5048.36₹39,090 Cr7.890.24%20.50%15.50%₹9,072 Cr₹816 Cr
Global Health
₹1,402.0067.76₹37,618 Cr9.520.04%15.20%17.40%₹4,683 Cr₹552 Cr
Median 7 companies₹927.1561.89₹59,927 Cr7.960.22%14.70%14.70%₹9,072 Cr₹906 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

37 Weak

Data confidence 100/100

pledge:67%

Category scores

Quality
36
Poor
Returns, margins, earnings quality 22% weight
Valuation
25
Poor
Cheap vs sector & own history 24% weight
Growth
44
Weak
Sales & profit trajectory 9% weight
Financial Health
32
Poor
Solvency, leverage, coverage 9% weight
Momentum
16
Poor
Trend strength, vol-adjusted 12% weight
Ownership
96
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has been maintaining a healthy dividend payout of 1,560%
  • Promoter holding has increased by 13.3% over last quarter.

Weaknesses

2
  • Stock is trading at 8.32 times its book value
  • Company has a low return on equity of 6.30% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish559
OscillatorsNeutral252
Moving AveragesStrong Bullish307

Key readings

RSI (14)
59.21
Neutral
MACD (12,26,9)
−10.18
Bullish
SMA (50)
721.42
Bearish
SMA (200)
714.73
Bullish

As of

Analyst Rating

Based on 12 analysts
BUY83%

10 of 12 analysts rate Buy, 1 Hold, 1 Sell.

As of

BUY
10
83%
HOLD
1
8%
SELL
1
8%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y−1.22%
5Y−11.61%
3Y+15.75%
1Y+12.20%
TTM+15.71%

Net profit

Net profit growth by window
10Y+48.84%
5Y+19.12%
3Y−3.49%
1Y−92.10%
TTM+3.71%

Operating cash flow

Operating cash flow growth by window
10Y+12.45%
5Y−16.00%
3Y−29.01%
1Y+54.35%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+10.37 pp
5Y+6.04 pp
3Y+3.92 pp
1Y+0.58 pp
TTM+0.15 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹5,931 Cr
Mar 2018₹6,721 Cr
Mar 2019₹7,963 Cr
Mar 2020₹8,652 Cr
Mar 2021₹8,608 Cr
Mar 2022₹10,253 Cr
Mar 2023₹2,994 Cr
Mar 2024₹3,699 Cr
Mar 2025₹4,138 Cr
Mar 2026₹4,643 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹98.00 Cr
Mar 2018₹282 Cr
Mar 2019₹367 Cr
Mar 2020₹315 Cr
Mar 2021₹178 Cr
Mar 2022₹601 Cr
Mar 2023₹475 Cr
Mar 2024₹212 Cr
Mar 2025₹5,408 Cr
Mar 2026₹427 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹615 Cr +244.3% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk high

Aster DM Healthcare trades at ₹719.55 as of 2026-11-04 with a market cap of ₹59,927 crore. The stock carries a PE of 117x TTM and a price-to-book of 14.91x, reflecting premium valuations relative to profitability metrics such as an 8.84% ROE and 9.71% ROCE. The company has delivered strong long-term stock price compounding at 27% CAGR over 3 and 5 years, though near-term profit growth has been muted at 2% TTM.

Bull Case 8
  • Promoter holding increased by 13.3% over the last quarter, signalling strong insider confidence in the business outlook.
  • The company has maintained an exceptionally high dividend payout ratio of 1,560%, returning substantial capital to shareholders.
  • Compounded profit growth over 10 years stands at 48%, demonstrating a long track record of earnings expansion.
  • Stock price CAGR of 27% over both 3-year and 5-year periods reflects sustained wealth creation for long-term holders.
  • Revenue growth has rebounded to 16% on a TTM basis and 16% on a 3-year compounded basis, indicating improving top-line momentum.
  • ROE improved to 11% in the last year from a 3-year average of 6%, suggesting an upward trend in capital efficiency.
  • Debt-to-equity ratio of 0.62 as of 2026-11-04 indicates a manageable leverage position for a healthcare services company.
  • ROCE of 9.71% provides a reasonable base return on deployed capital, with scope for expansion as the ROE trend improves.
Bear Case 8
  • The TTM PE of 117x is extremely elevated, implying the stock prices in significant future earnings growth that may not materialise.
  • Price-to-book ratio of 14.91x (and noted at 8.32x on an alternate basis) represents a steep premium to book value.
  • Three-year compounded profit growth is negative at -1%, indicating earnings have stagnated over the medium term despite revenue growth.
  • The 3-year average ROE of 6.30% is low, suggesting the company has struggled to generate adequate returns on shareholders' equity over this period.
  • Compounded sales growth over 5 years is -12% and over 10 years is -1%, pointing to structural top-line challenges on a longer horizon.
  • The stock is trading 19.3% below its 52-week high of ₹891.30, indicating meaningful price correction and potential overhead resistance.
  • TTM EPS of ₹6.15 against a share price of ₹719.55 yields a thin earnings yield of roughly 0.86%, well below risk-free rates.
  • The 1-year stock CAGR of -4% shows recent underperformance, suggesting the market may be reassessing the growth premium.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Aster DM Quality Care is demonstrating solid execution on both organic growth and post-merger integration, with 12% standalone revenue growth and a combined EBITDA of ₹2,013 crore. No notable headwinds surfaced in the latest news cycle. The key forward question is whether merger synergies continue to flow through to margins in coming quarters.

Positives 2
  • Strong post-merger combined revenue Oct 14

    Aster DM Quality Care reported FY26 combined proforma revenue of ₹9,273 crore and EBITDA of ₹2,013 crore post-merger, signaling scale benefits from the integration.

  • 12% standalone revenue growth Oct 14

    Standalone revenue rose 12% to ₹4,643 crore in FY26, indicating healthy organic growth in the India healthcare business.

Quarterly Results

₹ Cr
ASTERDM quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
841
929
955
974
1,002
1,086
1,050
1,000
1,078
1,197
1,186
1,182
1,311
Expenses
722
787
805
817
841
869
864
818
876
961
983
958
1,055
Operating Profit
119
142
149
156
161
217
186
182
202
236
202
224
256
OPM %
14%
15%
16%
16%
16%
20%
18%
18%
19%
20%
17%
19%
20%
Other Income
−17
−64
153
−40
5,120
35
9
5
29
28
0
37
−77
Interest
25
30
25
30
29
31
31
32
31
31
31
30
31
Depreciation
51
54
57
58
60
62
62
64
63
66
68
67
69
PBT
26
−7
220
28
5,191
159
102
91
136
167
103
163
78
Tax %
24%
120%
5%
108%
1%
33%
37%
6%
31%
27%
43%
6%
62%
Net Profit
20
−15
209
−2
5,152
106
64
86
94
121
59
154
29
EPS (₹)
0.1
−0.62
3.59
−0.48
103
1.94
1.14
1.58
1.65
2.12
1.01
2.71
0.31

Profit & Loss

₹ Cr
ASTERDM profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,876
5,250
5,931
6,721
7,963
8,652
8,608
10,253
2,994
3,699
4,138
4,643
4,876
Expenses
3,370
4,805
5,582
6,089
6,886
7,187
7,506
8,720
2,547
3,124
3,383
3,769
3,958
Operating Profit
506
445
349
632
1,077
1,465
1,103
1,533
447
575
756
875
918
OPM %
13%
8%
6%
9%
14%
17%
13%
15%
15%
16%
18%
19%
19%
Other Income
23
25
453
177
−155
−158
53
51
353
32
5,168
91
−13
Interest
79
189
371
204
205
391
334
307
96
119
133
132
123
Depreciation
144
243
322
298
306
586
618
641
192
220
249
264
270
PBT
306
38
108
308
410
330
205
637
511
268
5,542
570
511
Tax %
11%
78%
10%
8%
10%
5%
13%
6%
7%
21%
2%
25%
—
Net Profit
272
8
98
282
367
315
178
601
475
212
5,408
427
363
EPS (₹)
7
0.2
2.52
5.32
6.59
5.54
2.96
10.53
8.51
2.59
108
7.49
6.15
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
5%
40%
—

Balance Sheet

₹ Cr
ASTERDM balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
389
403
403
505
505
497
497
500
500
500
500
518
Reserves
1,096
17
1,472
2,327
2,709
2,775
2,875
3,080
3,574
3,686
2,554
3,683
Borrowings
1,091
3,321
2,758
2,352
2,788
5,605
4,804
5,282
6,075
1,758
2,392
2,594
Other Liabilities
1,834
2,003
2,171
2,296
2,926
3,528
3,444
3,661
4,687
12,039
1,154
1,280
Total Liabilities
4,409
5,743
6,804
7,479
8,928
12,405
11,620
12,521
14,836
17,983
6,600
8,076
Fixed Assets
2,237
2,507
3,520
3,738
4,289
7,124
6,749
7,009
9,052
3,175
3,920
4,242
CWIP
197
358
290
402
550
736
934
998
279
170
293
420
Investments
3
39
32
38
22
34
63
45
80
17
245
1,167
Other Assets
1,972
2,839
2,962
3,302
4,067
4,511
3,874
4,470
5,425
14,620
2,142
2,248
Total Assets
4,409
5,743
6,804
7,479
8,928
12,405
11,620
12,521
14,836
17,983
6,600
8,076

Cash Flow

₹ Cr
ASTERDM cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
236
203
361
537
601
1,223
1,569
1,314
1,834
158
425
656
Investing
−439
−775
−1,136
−522
−702
−658
−333
−563
−951
−878
6,015
−288
Financing
203
578
654
46
134
−675
−1,116
−686
−817
1,053
−6,358
−304
Net Cash Flow
−1
5
−122
61
33
−110
120
65
66
332
82
63
Free Cash Flow
−176
−536
−565
23
64
715
1,183
770
995
−601
70
179
CFO/EBITDA
51
53
116
93
61
88
143
89
424
40
71
93

Ratios

ASTERDM financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
93
79
84
93
100
86
72
285
23
23
24
Inventory Days
93
92
102
111
110
138
122
129
612
44
36
32
Days Payable
178
187
151
150
153
303
290
267
1,400
183
166
168
Cash Conversion Cycle
−2
−1
30
45
50
−65
−83
−66
−503
−116
−107
−112
Working Capital Days
69
68
6
59
28
8
5
5
−21
272
−32
−28
ROCE %
14%
6%
1%
7%
13%
12%
6%
10%
3%
4%
11%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aster DM Healthcare insights

65 extracted metrics across FY14–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 53.79%
  • DIIs 21.67%
  • FIIs 12.26%
  • Others 7.79%
  • Public 4.49%

66.85% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Aster DM Healthcare

What does Aster DM Quality Care Ltd do?
Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in GCC (Gulf Cooperation Council) countries and an emerging player in India.
Where is Aster DM Quality Care Ltd (ASTERDM) listed?
Aster DM Quality Care Ltd trades as ASTERDM on the NSE and under code 540975 on the BSE.
Which sector does Aster DM Quality Care Ltd belong to?
Aster DM Quality Care Ltd is classified under the Healthcare Services sector, in the Hospitals industry.
What is the PE ratio of Aster DM Quality Care Ltd?
Aster DM Quality Care Ltd trades at a PE ratio of 117.00 as of 4 Nov 2026, on earnings per share of ₹6.15, against a book value of ₹48.26 per share.
What is the 52-week high and low of Aster DM Quality Care Ltd?
Over the last 52 weeks Aster DM Quality Care Ltd has traded between ₹519.1 and ₹891.3 as of 4 Nov 2026.
Does Aster DM Quality Care Ltd pay dividends?
Aster DM Quality Care Ltd has a dividend yield of 0.44%.
What is the Return on Equity (ROE) of Aster DM Quality Care Ltd?
Aster DM Quality Care Ltd reported a return on equity of 11.30%. Its debt-to-equity ratio is 0.62.

Company Information

Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in GCC (Gulf Cooperation Council) countries and an emerging player in India. With an inherent emphasis on clinical excellence, it is one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare.

Website asterdmhealthcare.in
CEO Dr. Mandayapurath Azad Moopen DTCD, M.D., MBBS
Employees 15,334
Listed 26 Feb 2018
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ASTERDM.md for Aster DM Quality Care Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month